Joseph A Pidala
Overview
Explore the profile of Joseph A Pidala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jurdi N, Hamilton B, Pidala J, Onstad L, Mun C, Jain S, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39923937
Background: Ocular graft-versus-host disease (oGVHD) is one of the most common initial manifestations of chronic GVHD (cGVHD) leading to significant morbidity and reduced quality of life. Early detection of oGVHD...
2.
Baumrin E, Pidala J, Pidala J, Mitchell S, Mitchell S, Onstad L, et al.
Blood
. 2025 Jan;
PMID: 39808799
Sclerosis is a highly morbid manifestation of chronic GVHD (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome measure (PRO) for cGVHD-associated sclerosis is essential to advance...
3.
Pidala J, Pidala J, Kim J, Kalos D, Cutler C, Cutler C, et al.
Blood Adv
. 2024 Oct;
9(5):1040-1048.
PMID: 39454280
To examine the activity of ibrutinib in steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after the US Food and Drug Administration approval, we conducted a multicenter retrospective study. Data were standardly collected...
4.
Hoogland A, Barata A, Li X, Irizarry-Arroyo N, Jain M, Welniak T, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1219.e1-1219.e11.
PMID: 39306278
Chimeric antigen receptor (CAR) T-cell therapy has transformed survival outcomes in patients with relapsed and refractory large B-cell lymphoma (LBCL), but it is associated with a variety of side effects....
5.
Pidala J, Gooley T, Luznik L, Blazar B
Blood
. 2024 Jul;
144(13):1363-1373.
PMID: 39008818
Chronic graft-versus-host disease (cGVHD) is associated with morbidity, mortality, impaired quality of life, prolonged immunosuppressive therapy, and infection risk after allogeneic hematopoietic cell transplantation (HCT). Major strides have occurred in...
6.
Gillis N, Ebied A, Thompson Z, Pidala J
Haematologica
. 2024 Jun;
109(12):3952-3964.
PMID: 38899345
Hematopoietic cell transplantation (HCT) is the only potentially curative treatment option for many patients with hematologic malignancies. While HCT outcomes have improved drastically over the years, patients and clinicians continue...
7.
Pidala J, Onstad L, Baumrin E, Carpenter P, Cutler C, Arai S, et al.
Blood Adv
. 2024 Jun;
8(17):4651-4657.
PMID: 38885484
Cutaneous sclerosis, a highly morbid subtype of chronic graft-versus-host disease (GVHD), demonstrates limited treatment response under current National Institutes of Health (NIH) response measures. We explored novel sclerosis-specific response measures...
8.
Caprice T, Fan W, Kim J, Faramand R, Mishra A, Perez L, et al.
Am J Hematol
. 2024 Mar;
99(6):1196-1200.
PMID: 38546371
No abstract available.
9.
Saber W, Bansal A, Li L, Scott B, Sangaralingham L, Thao V, et al.
JCO Oncol Pract
. 2024 Jan;
20(4):572-580.
PMID: 38261970
Purpose: BMT CTN 1102 was a phase III trial comparing reduced-intensity allogeneic hematopoietic cell transplantation (RIC alloHCT) to standard of care for persons with intermediate- or high-risk myelodysplastic syndrome (MDS)....
10.
Lee C, Wang T, Chen K, Arora M, Brazauskas R, Spellman S, et al.
Transplant Cell Ther
. 2023 Oct;
30(1):97.e1-97.e14.
PMID: 37844687
The study aimed to determine the association of chronic graft-versus-host disease (cGVHD) diagnosis and severity with the development of subsequent neoplasms (SN) and nonmalignant late effects (NM-LE) in 2-year disease-free...